Remix Therapeutics to Present at 5th Annual RNA-Targeted Drug Discovery Summit
December 08, 2022 08:00 ET
|
Remix Therapeutics
CAMBRIDGE, Mass., Dec. 08, 2022 (GLOBE NEWSWIRE) -- Remix Therapeutics (Remix), a biotechnology company developing small molecule therapies to modulate RNA processing and address the underlying...
Remix Therapeutics Appoints Zaven Kaprielian, Ph.D., as Chief Scientific Officer
December 15, 2021 08:00 ET
|
Remix Therapeutics
CAMBRIDGE, Mass., Dec. 15, 2021 (GLOBE NEWSWIRE) -- Remix Therapeutics, a biotechnology company developing small molecule therapies designed to reprogram RNA processing and address the underlying...
Remix Therapeutics to Present at 4th Annual RNA-Targeted Drug Discovery Summit
December 06, 2021 08:00 ET
|
Remix Therapeutics
CAMBRIDGE, Mass., Dec. 06, 2021 (GLOBE NEWSWIRE) -- Remix Therapeutics, a biotechnology company developing small molecule therapies designed to reprogram RNA processing and address the underlying...